This trial has been completed.

Condition bacterial infection
Sponsor University of California, Irvine
Collaborator Copan Diagnostics, Inc.
Start date October 2008
End date June 2014
Trial size 136 participants
Trial identifier NCT00915213, 2008-6418


The purpose of this study is to discover how often certain bacteria are found in the rectum at the time of a prostate needle biopsy to diagnose prostate cancer. Certain bacteria are of importance because they can cause serious infection. Antibiotics that urologists commonly use to prevent these bacteria from causing infection are no longer effective. Many physicians around the world are noting increased infections with antibiotic resistant bacteria. Therefore; despite treating patients who are to undergo prostate biopsy with antibiotics, certain patients are being readmitted to the hospital with a serious infection. In order to study the incidence of these particular bacteria, the best method is to culture the bacteria at the time of the biopsy. This involves one rectal culture swab just prior to needle biopsy of the prostate. Once the incidence of these bacteria is known we may take steps to prevent the serious infections that occur as a result of prostate biopsy.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective
Men who undergo repeat prostate biopsy

Eligibility Criteria

Male participants at least 18 years old.

Inclusion Criteria: - adult males - repeat prostate biopsy Exclusion Criteria: - first time prostate biopsy - minors

Additional Information

Official title Incidence of Fluoroquinolone Resistant Enterobacteraciae in Patients Undergoing Repeat Ultrasound Guided Prostate Biopsy
Principal investigator Atreya Dash, MD
Trial information was received from ClinicalTrials.gov and was last updated in December 2016.
Information provided to ClinicalTrials.gov by University of California, Irvine.